BIONEER CORPORATION

Bioneer Unveils MegaBase Synthesizer, Revolutionizing High-Throughput Gene Synthesis with
Enhanced Capacity and Cost-Efficiency

                                                                                                

DAEJEON, South Korea – May 21, 2025 – Bioneer Corporation (KOSDAQ: 064550), a pioneering biotechnology company with over 30 years of expertise in molecular and synthetic biology, today announced significant advancements in its gene synthesis capabilities, highlighted by the features of its new MegaBase Synthesizer. This cutting-edge system dramatically boosts oligo pool production and offers enhanced cost-effectiveness, reinforcing Bioneer's position as a leader in the synthetic biology field.

The newly detailed MegaBase Synthesizer is a high-efficiency platform capable of simultaneously synthesizing a staggering 56,448 diverse oligo pools, designed for the assembly of up to 1,152 genes in a single run within a day. This system utilizes advanced phosphoramidite chemistry, and its high-density integration allows for the production of a significantly higher number of oligo pools than enzyme-based synthesis methods. Furthermore, it successfully addresses the low-concentration issues often associated with microarray-based oligo synthesis, positioning it as a groundbreaking parallel oligo synthesizer.

A key strategic advantage for Bioneer is its in-house development and production of core raw materials used in the synthesis process. This vertical integration allows the company to offer high-quality gene synthesis services with highly competitive pricing. Leveraging the MegaBase Synthesizer, Bioneer now boasts a maximum monthly oligo pool production capacity of 50 megabases (Mb). The company also highlighted that its 1/1000 scale synthesis process has led to a dramatic reduction in raw material costs, further enhancing its service value.

"The MegaBase Synthesizer represents a significant leap forward in our mission to provide researchers with powerful and accessible tools for synthetic biology," said a Bioneer spokesperson. "By combining high-throughput capacity with our cost-effective in-house material production, we are breaking down barriers for large-scale genomic projects."

This development complements Bioneer's established advanced synthesis capabilities. The company utilizes state-of-the-art synthesizers, including its proprietary HT-oligo™ Synthesizer alongside the broader Megabase Synthesizer line, to efficiently support large-scale synthetic biology projects.

Continued Commitment to Innovation and Service Excellence

Bioneer’s gene synthesis service is built on a foundation of proprietary technology and stringent quality control:

• Competitive and Transparent Pricing: Bioneer offers competitive pricing, with sequence lengths below 400bp available at a flat price, and a fixed price per base pair for sequences up to 100,000bp. This model supports cost-effective synthesis for diverse project scales. Additional discounts of at least 15% for bulk orders and B2B contracts are applied, with intellectual property securely preserved.
• Proprietary Oligo Design Technology: Bioneer’s oligo design technology achieves a success rate exceeding 99% for initial fragment assembly. The core algorithm of this technology standardizes oligo lengths to overcome potential concentration variances during synthesis and maximizes the efficiency of assembling small fragments. This high success rate is key to developing fully automated gene synthesis processes. In 2024, Bioneer secured R&D funding from the Ministry of Trade, Industry and Energy (MOTIE) to develop autonomous manufacturing systems using artificial intelligence, aiming to automate the production of thousands of initial fragments with minimal human intervention.
• Innovative Fragment Assembly Technology: Bioneer employs a range of advanced techniques:
• Gibson Assembly: For constructs smaller than 3 kb.
• Proprietary Fragment Assembly: For mid-sized constructs (3 kb to 15 kb), capable of assembling over 20 fragments concurrently. While conventional fragment assembly often involves fragments of varying lengths, Bioneer's technology cuts customer-ordered sequences into uniform sizes for assembly. This advanced technique boosts efficiency and facilitates the synthesis of complex genes.
• In Vivo Assembly: For large constructs (15 kb to 100 kb), facilitating highly complex DNA sequence synthesis.
• Single Colony-Based Verification for 100% Accuracy: Bioneer guarantees 100% sequence accuracy for synthesized genes through Sanger sequencing of single colonies, delivering only perfectly matched clones to customers.
• Comprehensive Additional Services: Bioneer offers cloning services (into proprietary or customer vectors), mutagenesis, mRNA synthesis (including 5’ capping and 3’ poly(A) tailing), gene-to-protein synthesis, and custom donor DNA templates for CRISPR applications. Complimentary codon optimization, Rapid Gene Synthesis, and AccuGeneBlock DNA fragments further enhance their offerings.

Notes and Considerations: Pricing and turnaround times may be adjusted for complex sequences (e.g., extreme GC content or repetitive sequences). Synthesis of potentially hazardous sequences requires customer consent beforehand, and genes toxic to E. coli are typically delivered as linear PCR products. Products and data are archived for six months post-delivery unless customers request immediate disposal.

Conclusion With the enhanced capabilities of the MegaBase Synthesizer, Bioneer significantly strengthens its robust and reliable gene synthesis solutions for the synthetic biology community. These advancements in synthesis capacity, coupled with competitive pricing, proprietary technologies, and stringent quality control, position Bioneer to effectively meet the evolving needs of researchers in academia, biotechnology, and the pharmaceutical industry worldwide.

About Bioneer Corporation: Established in 1992, Bioneer Corporation is a pioneering biotechnology company based in South Korea, with over 30 years of expertise in molecular and synthetic biology. As the first Korean company to offer gene synthesis services, Bioneer has developed a comprehensive range of services, from oligonucleotide synthesis to protein production. ###